Abstract: The invention features a polymerizable composition that comprises a free-radically polymerizable acidic resin, and a photoinitiator system comprising a polycyclic aromatic component. The photoinitiator system may also contain a visible light sensitizer, an iodonium salt, and a tertiary amine.

Abstract: The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.

Abstract: Addition-fragmentation agents of the formula are disclosed having the following functional groups: 1) a labile addition-fragmentation group that can cleave and reform to relieve strain, 2) a free-radically polymerizable group, and 3) a surface-modifying functional group that associates with the surface of a substrate.

Abstract: An intermediate compound for forming a RAFT agent is provided that can have the formula: where n is an integer from 1 to 20; m is an integer from 0 to 20; R1 is H, an alkyl group, or a cyano group; R2 is H, an alkyl group, or a cyano group; Y is OH, COOH, or NH2; and X is OH, COOH, NH2, a nitrobenzyl, benzyl, or para-methyl benzyl group. A RAFT agent is also provided that comprises a thiocarbonylthio-containing organic compound having a phosphonic end group. A method is also provided for forming a polymer chain on a surface of a nanoparticle utilizing the RAFT agent, along with nanoparticles and nanocomposites formed therefrom.

Abstract: Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment.

Abstract: Addition-fragmentation agents of the formula are disclosed having the following functional groups: 1) a labile addition-fragmentation group that can cleave and reform to relieve strain, 2) a free-radically polymerizable group, and 3) a surface-modifying functional group that associates with the surface of a substrate.

Abstract: Synthons for the synthesis of phosphonates prodrugs POM and POC, especially for direct Cross Metathesis.

Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.

Abstract: Technologies are generally described for a system and method effective to prepare a flame retardant. In one example, a method may include copolymerizing a mixture of monomers. The mixture of monomers may include at least one dicarboxylic acid monomer, at least one diamine monomer, and at least one monomer having the formula (I) wherein R1 is hydroxyl, halogen, alkoxy, or aryloxy; wherein R2 is hydroxyl, halogen, alkoxy, or aryloxy; wherein R3 is H or -L-R5; wherein R4 is H or L-R5; wherein if R3 is H, then R4 is L-R5; wherein L is alkyl, cycloalkyl, aryl, heteroaryl, or —(R6-O—R7)n-; wherein R6 is alkyl, cycloalkyl, aryl, or heteroaryl, wherein R7 is alkyl, cycloalkyl, aryl, or heteroaryl, wherein n is an integer from 1 to 12; wherein R5 is a flame retarding moiety comprising P, N, halogen, or B; and wherein q is an integer from 1 to 12.

Abstract: The present invention provides a nonaqueous electrolytic solution capable of improving electrochemical characteristics at high temperatures, which comprises at least one organic phosphorus compound represented by the following general formula (I), an energy storage device using the nonaqueous electrolytic solution, and a specific organic phosphorus compound. (In the formula, R1 and R2 each independently represent an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a cycloalkoxy group, an alkenyloxy group, an alkynyloxy group, a halogenoalkyl group, a halogenoalkoxy group, an aryl group, or an aryloxy group; R3 and R4 each independently represent a hydrogen atom, a halogen atom, or an alkyl group; m is an integer of from 1 to 4, n is 0 or 1, q is 1 or 2. When q is 1 and n is 0, X represents an alkoxy group, an alkynyloxy group, an alkyloxyalkoxy group, an aryloxy group, etc.

Abstract: The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.

Abstract: The invention relates to curable compositions which comprise epoxy resins, amino hardeners, and a phosphonate of the formula I. Addition of phosphonate of the formula I can give cured epoxy resins which have not only improved flame retardants but also an increased glass transition temperature when comparison is made with the corresponding resins without said addition.

Abstract: The present invention describes dental adhesive compositions used for bonding dental biomaterials to hard tissue comprising a polymerizable blend of one or more newly synthesized low shrinkage, stable, multifunctional compounds, where the compounds are acidic-methacrylate derivatives, having excellent properties of bonding the hard tooth substance (enamel or dentin) to dental restorative materials, and present high quality marginal sealing between the tooth and the material thus bond and improved storage stability

Abstract: The compound according to the invention has the following developed formula IX: wherein: X=PO(OH)2; SO2(OH); PO(OH)(Xaa)m or SO2(Xaa)m; A=H; OH; NH2 or akyl (1-6C); n=1 to 4; Y=—CO—OR2; —CO—NR3R4; —O—CO—R2; —C?CR2; R2=an alkyl, aryl, aralkyl, acyl, sulfonyl, sugar or alkoxy chain of 1 to 24 carbon atoms, linear, branched or cyclic, with or without substitutions, saturated or not, hydroxylated or not, sulfurated or not; R5=OH, O-alk (1-6C), (Xaa)m, NH2 or NH-alkyl(1-6C); Xaa=peptide of m aminoacids Xaa with m from 1 to 10; The compound is preferably phosphated, obtained from malic acid and having the following developed formula: A cosmetic composition comprising the compound of the present invention can improve the general condition of the skin, for example hydration, lightening and mechanical properties.

Abstract: This invention relates to novel compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

Abstract: Synthons for the synthesis of phosphonates prodrugs POM and POC, especially for direct Cross Metathesis.

Abstract: A dispersant comprising a polyester chain obtainable by polymerising a hydroxy carboxylic acid or lactone thereof such as ?-caprolactone with a cyclic alkylene carbonate such as 5,5-dimethyltrimethylene carbonate. The dispersant may be in the form of a phosphate ester where the polyester chain is reacted with a phosphating agent such as polyphosphoric acid or the polyester chain may be attached to a polyamine or polyimine such as polyethyleneimine.

Abstract: The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.

Abstract: Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment.

Abstract: It is an object of the present invention to provide a leukotriene receptor antagonist that can be conveniently prepared from a natural source. The object has been achieved by finding that a marine product such as a squid phospholipid extract or an Akiami paste shrimp phospholipid extract contains the antagonists of BLT and CysLT1, which are leukotriene receptors. Therefore, the present invention provides a dietary composition and a pharmaceutical composition for inhibiting the activity of leukotriene receptors, containing a squid phospholipid extract or an Akiami paste shrimp phospholipid extract.

Abstract: Methods and kits for decomposing organophosphorus compounds in non-aqueous media at ambient conditions are described. Insecticides, pesticides, and chemical warfare agents can be quickly decomposed to non-toxic products. The method comprises combining the organophosphorus compound with a non-aqueous solution, preferably an alcohol, comprising metal ions and at least a trace amount of alkoxide ions. In a first preferred embodiment, the metal ion is a lanthanum ion. In a second preferred embodiment, the metal ion is a transition metal.

Abstract: The present invention relates to a suspension stabilizer for dispersing inorganic nanoparticles into aqueous medium. More particularly, the present invention is directed to a biocompatible suspension stabilizer which comprises phosphoryl domain having an affinity to the surface of an inorganic nanoparticle and poly(ethylene glycol) having an affinity to the aqueous medium, and which is prepared by reacting a biocompatible poly(ethylene glycol)-derivatized polymer with phosphine oxide having a leaving group.

Abstract: The present invention relates to a method of using a compound of formula (I): (I) or formula (II) (II) wherein R1 and R2 independently represent a C3 to C18 alkyl group or alkenyl group, and R3 is selected from the group consisting of —H, —(CH2CH2N+(CH3)3), —(CH2CH2NH3+), —(CH2CH(NH3+)COOH), —(CH2CH(OH)CH2OH), and —(C6H11O6) to impart a mouthfeel effect, especially to low calorie beverages, such as teas, coffees and cola's.

Abstract: A phosphine-based polymer having Formula (I) is provided. The invention also provides a poly(lactic acid) material including poly(lactic acid) and the disclosed phosphine-based polymer, wherein the phosphine-based polymer has a weight ratio of 0.05-10 parts by weight, based on 100 parts by weight of the poly(lactic acid).

Abstract: By using phosphorus compounds, diesters of dicarbonic acid may be stabilized against thermal and chemical decomposition over a relatively long period. Mixtures of diesters of dicarbonic acid and phosphorus compounds are outstandingly suitable for preserving foods.

Abstract: The present invention relates to a phosphate-based acrylate crosslinking agent for polymer electrolyte and a polymer electrolyte composition comprising the phosphate-based acrylate crosslinking agent, and in particular to a phosphate-based acrylate crosslinking agent where a phosphate-based compound is introduced with a polyalkylene oxide group and an acrylate group and a polymer electrolyte composition comprising the phosphate-based acrylate crosslinking agent. The polymer electrolyte composition can be applied to electrolyte thin film and polymer electrolyte of small and large capacity lithium-polymer secondary battery due to its superior ionic conductivity and electrochemical and thermal stability, where the physical properties of electrolyte composition may be controlled by means of the length of polyalkylene oxide of the crosslinking agent.

Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.

Abstract: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.

Abstract: The invention relates to organophosphorus compounds comprising a polysulfide bridge, to their process of preparation and to their use as coupling agent between an inorganic or metal filler and an elastomer. The compounds correspond to the formula (I) (RO)2?tR1tP(O)—Ox—(CH2)y—Sz—(CH2)y—Ox—P(O) (OR)2?tR1t in which R represents a hydrogen , an alkyl, an aryl, a trialkylsilyl, a trialkylamino or an alkali metal; R1 represents an alkyl or an aryl; x is 0 or 1; y is an integer from 1 to 22, preferably from 2 to 4; z is equal or larger than 3, t is 0 or 1.

Abstract: A compound represented by the following general formula (IA) or a salt thereof: wherein Ar1 represents hydrogen atom or an aryl group having at least one iodine atom as a substituent; Ar2 represents an aryl group having at least one iodine atom as a substituent; L1 and L2 independently represent a divalent bridging group of which main chain contains 6 or more carbon atoms; L3 represents a single bond or a divalent bridging group of which main chain contains 1 to 6 carbon atoms and one oxygen atom; X represents a functional group containing at least one heteroatom, provided that, when L3 is a single bond, X represents a functional group other than hydroxyl group. The compound can be used as a membrane component of liposomes, and the liposomes can be used as a contrast medium for X-ray radiography.

Abstract: A dispersant comprising a polyester chain obtainable by polymerising a hydroxy carboxylic acid or lactone thereof such as E-caprolactone with a cyclic alkylene carbonate such as 5,5-dimethyltrimethylene carbonate. The dispersant may be in the form of a phosphate ester where the polyester chain is reacted with a phosphating agent such as polyphosphoric acid or the polyester chain may be attached to a polyamine or polyimine such as polyethyleneimine.

Abstract: A dispersant which is a phosphate ester of a polymer which contains at least one ether group and a poly(oxyalkylenecarbonyl) chain (POAC chain) derivable from two or more different hydroxycarboxyl acids or lactones thereof. Also disclosed is the use of the dispersants in paints and printing inks including millbases. The preferred dispersants are phosphate esters of an alkyl end-capped poly(oxyalkylenecarbonyl) chain alcohol where the POAC chain is derived from &egr;-caprolactone and &dgr;-valerolactone and the alkyl group is derived from a monohydroxypolyalkyleneglycol.

Abstract: A dispersant which is a phosphate ester of a polymer which contains at least one ether group and a poly(oxyalkylenecarbonyl) chain (POAC chain) derivable from two or more different hydroxycarboxyl acids or lactones thereof. Also disclosed is the use of the dispersants in paints and printing inks including millbases. The preferred dispersants are phosphate esters of an alkyl end-capped poly(oxyalkylenecarbonyl) chain alcohol where the POAC chain is derived from &egr;-caprolactone and &dgr;-valerolactone and the alkyl group is derived from a monohydroxypolyalkyleneglycol.

Abstract: The present invention relates to prodrugs of NAALADase inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat glutamate abnormalities and prostate diseases.

Abstract: This invention provides analogues of phosphatidylinositol-phosphates modified at one or more selected inositol-hydroxyls and optionally carrying reporter or anchoring groups attached in the lipid or the inositol residues, and, the synthetic intermediates and methods for the preparation of these analogues. The analogues are useful as research reagents in biomedical studies related to structure, function and therapeuticals, including reference materials for analyzing the metabolic products in safety and efficacy studies of 2- and/or 3-hydroxyl modified inositols and phosphatidylinositols as drug candidates.

Abstract: The present invention provides novel compounds comprising cellular phosphoinositides and analogues tagged with stable or radioactive isotopes. The present invention also provides novel methods for the preparation of the said phosphoinositides by syntheses, and novel key intermediates of synthesis; the novel methods of synthesis are applied also for the preparation of the phosphoinositides in non-labelled form. In addition, the present invention discloses a class of novel compounds as isotope labelled key precursors of labelled phosphoinositides. These precursors are derivatives of the target phosphoinositides, labelled with stable or radioactive isotopes, wherein OH and phosphate groups are blocked with temporary protecting groups.

Abstract: The present invention relates to a process for the preparation of phosphinic acid esters, which comprises a) reacting elemental yellow phosphorus with alkylating agents in the presence of a base to give a mixture which comprises, as principal constituents, the (metal) salts of alkylphosphonous, phosphorous and hypophosphorous acids, b) esterifying the principal constituents of the mixture from a) to give an ester mixture, c) isolating the ester of the alkylphosphonous acid from the ester mixture, d) adding the resultant ester of the alkylphosphonous acid onto an olefin containing a functional group. The invention likewise relates to the use of the phosphinic acid esters prepared by this process, inter alia as flame retardants and precursors for further syntheses.

Abstract: The present invention relates to the preparation and biological activity of 3-deoxy-D-myo-inositol ether lipid analogs as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. The compounds of the present invention are useful as anti-tumor agents which effectively inhibit the growth of mammalian cells.

Abstract: This invention provides analogues of phosphatidylinositol-phosphates modified at one or more selected inositol-hydroxyls and optionally carrying reporter or anchoring groups attached in the lipid or the inositol residues, and, the synthetic intermediates and methods for the preparation of these analogues. The analogues are useful as research reagents in biomedical studies related to structure, function and therapeuticals, including reference materials for analyzing the metabolic products in safety and efficacy studies of 2- and/or 3-hydroxyl modified inositols and phosphatidylinositols as drug candidates.

Abstract: The present invention relates to a (a) novel dicarboxy alkyl phosphate esters, (b) a method for the preparation of said phosphate ester and (c) application of said phosphate ester in industrial and personal care applications. The compounds of the present invention are made by reacting epoxy succinic acid and a salt of an alkyl phosphate ester under aqueous conditions. The resulting compound is quite stable and offers excellent emulsification properties.

Abstract: Addition of an oxidation agent to completely or partially water-based organophosphate pesticide formulations or solid organophosphate pesticide formulations improves the chemical stability of the pesticide, minimizes formation of toxic isomeric compounds, and eliminates the development of mercaptan and sulfide smell.

Abstract: Stable, enzymatically triggered chemiluminescent 1,2-dioxetanes with improved water solubility and storage stability are provided as well as synthetic processes and intermediates used in their preparation. Dioxetanes further substituted with two or more water-solubilizing groups disposed on the dioxetane structure and an additional fluorine atom or lower alkyl group provide superior performance by eliminating the problem of reagent carryover when used in assays performed on capsule chemistry analytical systems. These dioxetanes display substantially improved stability on storage. Compositions comprising these dioxetanes, a non-polymeric cationic surfactant enhancer and optionally a fluorescer, for providing enhanced chemiluminescence are also provided.

Abstract: This invention relates to compositions for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound hearing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and in particular, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, treating, preventing or ameliorating protozoan infection, or inhibiting histone deacetylase in cells. The compositions of the invention are to and the methods of the invention use oxyalkalene phosphate compounds.

Abstract: Lipid prodrugs of phosphonoacids and their analogs that have increased antiviral activity over the parent drugs in inhibiting cytomegalovirus and other susceptible viruses.

Abstract: Membrane-permeant phosphoinositides, including phosphatidylinositol phosphate esters, are described. A membrane-permeant phosphoinositide includes groups that neutralize the charges of the phosphate moieties of the phosphoinositide. A cell can be treated with the membrane-permeant phosphoinositide, which is then absorbed into the cell. The neutralizing groups can be removed intracellularly to afford the charged phosphoinositide.

Abstract: To provide 2,5-dicarboxyphenyl phosphonic acid and a process for the preparation thereof, comprising the steps of: forming a reaction liquid phase by supplying a 2,5-dialkylphenyl phosphonic acid, a solvent, a cobalt salt, a manganese salt and/or a cerium salt, and bromine or a bromine compound into a reaction zone; and supplying oxygen into the reaction liquid phase by bringing an oxygen-containing gas into contact with the reaction liquid phase by supplying an oxygen-containing gas into the above-mentioned reaction zone.

Abstract: Compounds of the formula ##STR1## where m and n are integers 0 to 10 and m+n equals 0 to 10, (a) X is O or S(b) Z is a covalent bond; a monocyclic or polycyclic carbocycle ring moiety; or a monocyclic or polycyclic heterocyclic ring moiety containing one or more heteroatoms selected from O, S, or N;(c) Q is covalent bond; O; or S;(d) R is COOH, SO.sub.3 H, PO.sub.3 H.sub.2, or P(O)(OH)R.sup.4, wherein R.sup.4 is C.sub.1 -C.sub.8 alkyl;(e) R.sup.1, R.sup.2 and R.sup.5 are as defined in the claims.are useful in the treatment of calcium and phosphate elated disorders, such as arthritis and the like.

Abstract: Stable, enzymatically triggered chemiluminescent 1,2-dioxetanes with improved water solubility are provided. Dioxetanes further instituted with two or more water-solubilizing groups disposed on the dioxetane structure provide superior performance by eliminating the problem of reagent carryover when used in assays performed on capsule chemistry analytical systems. Compositions comprising a dioxetane with two or more water-solubilizing groups, a non-polymeric cationic surfactant enhancer and optionally a fluorescer, for providing enhanced chemiluminescence are also provided.

Abstract: Inks, particularly inks for ink jet printing, contain at least one compound of the formula I ##STR1## as a stabilizer. The symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.3 ' and R.sub.4 ' are as defined in claim 1. The compounds are in part novel and are suitable for use as light stabilizers for organic materials.

Abstract: The synthesis of a non-halogen flame retardant oligomer containing highly pendnat phosphorus moieties is disclosed. Diols, unsaturated double bond-containing dicarboxylic acids or acid anhydrides and saturated dicarboxylic acids or acid anhydrides are first esterified to form an oligomeric unsaturated polyester, and then a phsophorus-containing compound is grafted onto the oligomeric unsaturated polyester through addtion reaction in the presence of a selected metal complex catalyst.